Biosimilar Developers Must Scale Mountains of Data
Source: Parenteral Drug Association (PDA)
By Rebecca Stauffer and Walter Morris, PDA
Powerful Analytics, Strong Science Permit Biosimilars
The U.S. FDA approved Sandoz’s filgrastim product, Zarxio, a biosimilar of Amgen’s Neupogen. This was a big step for the Agency, and one some feel was long in coming. The same product was approved for marketing in Europe six years earlier (under the name Zarzio). Incidentally, the following year, the Biologics Price Competition and Innovation Act (BPCIA) was signed into law in the United States, which was seen as opening the gateway for biosimilars in the United States
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
Parenteral Drug Association (PDA)
This website uses cookies to ensure you get the best experience on our website. Learn more